The Additional Value of Activated Clotting Time-Guided Heparinization During Interventions for Peripheral Arterial Disease.
Liliane C RoosendaalMila RadovićMax HoebinkArno M WiersemaJan D BlankensteijnVincent JongkindPublished in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2023)
Heparin is administered during arterial interventions for peripheral arterial disease (PAD) to decrease the risk of arterial (thrombo)embolic complications (ATEC) during or shortly following surgery. The effect of heparin is unpredictable in the individual patient, and the optimal dosage of this anticoagulant has not yet been established. Using the activated clotting time (ACT), the anticoagulatory effect of heparin can be monitored periprocedurally. Previous research on the incidence of both ATEC and bleeding complications, or on the optimal dosage of heparin administration, is scarce. This study aims to investigate the incidence of ATEC and bleeding complications between 2 different dosage protocols of heparin-a standard bolus of 5000 IU or ACT-guided heparinization-and thereby provide clarity on the optimal dose of heparin during peripheral arterial interventions for PAD.